{"created":"2023-05-15T15:01:49.390868+00:00","id":83857,"links":{},"metadata":{"_buckets":{"deposit":"546cd4e1-176c-458b-9d49-5b59bc2fc786"},"_deposit":{"created_by":1,"id":"83857","owners":[1],"pid":{"revision_id":0,"type":"depid","value":"83857"},"status":"published"},"_oai":{"id":"oai:repo.qst.go.jp:00083857","sets":["10:29"]},"author_link":["1011696","1011688","1011692","1011693","1011694","1011690","1011691","1011695","1011697","1011689"],"item_10005_date_7":{"attribute_name":"発表年月日","attribute_value_mlt":[{"subitem_date_issued_datetime":"2021-11-05","subitem_date_issued_type":"Issued"}]},"item_10005_description_5":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"【背景】⽩⾦核種189, 191Ptは適度な半減期でγ線とAuger電⼦を放出することから，抗腫瘍⽩⾦製剤のトレーサー研究への利⽤，さらに⽩⾦の\nDNA結合性を活かしたAuger電⼦治療への応⽤などが期待される。本研究では，これまで製造開発を⾏った[189, 191Pt]cisplatin (radiocisplatin)について，in-vitro/vivoでの薬剤分布評価とDNA障害に関する細胞での評価を⾏った。【⽅法】培養がん細胞や担がんマウスモデル\nを⽤いた薬剤分布及びγH2AXの免疫染⾊によるDNA⼆重鎖切断(DSBs)を評価した。【結果】Radio-cisplatinはキャリアの有無に関わらず細胞\n内に取り込まれ，その⼀部が核内に移⾏してDNAと結合することが⽰された。また，担がんマウスにおける薬剤の腫瘍への取り込みや腎排泄が\n確認された。免疫染⾊では，対照群(⾮放射性cisplatin，⽣理⾷塩液)と⽐較して，radio-cisplatinは細胞に多くのDSBsを引き起こした。【結\n論】in-vitro/vivoのトレーサー研究におけるradio-cisplatinの有⽤性とともに，DNAに結合したオージェ電⼦がDSBsを誘発する可能性が⽰唆\nされた。","subitem_description_type":"Abstract"}]},"item_10005_description_6":{"attribute_name":"会議概要（会議名, 開催地, 会期, 主催者等）","attribute_value_mlt":[{"subitem_description":"第61回日本核医学会学術総会","subitem_description_type":"Other"}]},"item_access_right":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"metadata only access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_14cb"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"尾幡, 穂乃香"}],"nameIdentifiers":[{"nameIdentifier":"1011688","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"辻, 厚至"}],"nameIdentifiers":[{"nameIdentifier":"1011689","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"永津, 弘太郎"}],"nameIdentifiers":[{"nameIdentifier":"1011690","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"小川, 美香子"}],"nameIdentifiers":[{"nameIdentifier":"1011691","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"張, 明栄"}],"nameIdentifiers":[{"nameIdentifier":"1011692","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Honoka, Obata","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"1011693","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Atsushi, Tsuji","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"1011694","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Kotaro, Nagatsu","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"1011695","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Mikako, Ogawa","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"1011696","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Zhang, Ming-Rong","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"1011697","nameIdentifierScheme":"WEKO"}]}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"conference object","resourceuri":"http://purl.org/coar/resource_type/c_c94f"}]},"item_title":"[189, 191Pt]cisplatinの薬剤分布とDNA障害性の評価","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"[189, 191Pt]cisplatinの薬剤分布とDNA障害性の評価"}]},"item_type_id":"10005","owner":"1","path":["29"],"pubdate":{"attribute_name":"公開日","attribute_value":"2021-11-01"},"publish_date":"2021-11-01","publish_status":"0","recid":"83857","relation_version_is_last":true,"title":["[189, 191Pt]cisplatinの薬剤分布とDNA障害性の評価"],"weko_creator_id":"1","weko_shared_id":-1},"updated":"2023-05-15T18:58:54.014382+00:00"}